Shares of Endocyte Inc. (NASDAQ:ECYT) rose 3.8% on Tuesday . The stock traded as high as $3.05 and last traded at $3.03, with a volume of 68,765 shares trading hands. The stock had previously closed at $2.92.

ECYT has been the subject of several research analyst reports. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Endocyte in a research note on Tuesday, July 12th. Zacks Investment Research raised shares of Endocyte from a “sell” rating to a “hold” rating in a research note on Thursday, May 26th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Endocyte presently has an average rating of “Buy” and a consensus target price of $8.69.

The firm’s market cap is $125.53 million. The stock’s 50-day moving average is $3.07 and its 200 day moving average is $3.40.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/endocyte-inc-ecyt-stock-price-up-3-8.html

Endocyte (NASDAQ:ECYT) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.01. Endocyte had a negative net margin of 58,957.14% and a negative return on equity of 24.71%. During the same quarter in the previous year, the firm posted ($0.25) earnings per share. On average, equities research analysts predict that Endocyte Inc. will post ($1.12) EPS for the current year.

A number of hedge funds have recently made changes to their positions in ECYT. Concannon Wealth Management LLC boosted its stake in shares of Endocyte by 6.5% in the second quarter. Concannon Wealth Management LLC now owns 32,639 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 2,000 shares in the last quarter. Nationwide Fund Advisors boosted its stake in Endocyte by 31.4% in the second quarter. Nationwide Fund Advisors now owns 33,417 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 7,989 shares during the period. ProShare Advisors LLC boosted its stake in Endocyte by 1.7% in the second quarter. ProShare Advisors LLC now owns 36,028 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 585 shares during the period. Stifel Financial Corp purchased a new stake in Endocyte during the second quarter valued at $127,000. Finally, Cribstone Capital Management LLC boosted its stake in Endocyte by 45.5% in the second quarter. Cribstone Capital Management LLC now owns 47,349 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 14,808 shares during the period. 36.48% of the stock is owned by institutional investors.

About Endocyte

5 Day Chart for NASDAQ:ECYT

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.